NCT04014530View on ClinicalTrials.gov

Pembrolizumab With Ataluren in Patients With Metastatic pMMR and dMMR Colorectal Carcinoma or Metastatic dMMR Endometrial Carcinoma: the ATAPEMBRO Study

PHASE1/PHASE2UnknownINTERVENTIONAL
Enrollment

47

Participants

Timeline

Start Date

August 1, 2019

Primary Completion Date

June 1, 2023

Study Completion Date

August 1, 2023

Conditions
Colorectal CancerEndometrium Cancer
Interventions
DRUG

Ataluren + Pembrolizumab

Ataluren and Pembrolizumab combination therapy

Trial Locations (1)

1105 AZ

RECRUITING

Amsterdam UMC, AMC, Amsterdam

Sponsors

Collaborators (1)

PTC Therapeutics
All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

collaborator

PTC Therapeutics

INDUSTRY

lead

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

OTHER

NCT04014530 - Pembrolizumab With Ataluren in Patients With Metastatic pMMR and dMMR Colorectal Carcinoma or Metastatic dMMR Endometrial Carcinoma: the ATAPEMBRO Study | Biotech Hunter | Biotech Hunter